Latest Breaking News On - ஹோலி மானிங் - Page 1 : comparemela.com
10 Best Concerts of the Week: Speedealer, Robert Earl Keen, Cure for Paranoia and More
dallasobserver.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dallasobserver.com Daily Mail and Mail on Sunday newspapers.
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
– Supplemental New Drug Application Planned for Submission in Q1 2021 –
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in .
Agios Pharmaceuticals, Inc.January 17, 2021 GMT
CAMBRIDGE, Mass., Jan. 17, 2021 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today reported a full analysis of the final data, including mature overall survival (OS) results, from its global Phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib tablets) in patients with previously treated isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma. Data from the study were featured in an oral presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI), which is being held virtually January 15-17, 2021.
Published: Dec 21, 2020
CAMBRIDGE, Mass., Dec. 21, 2020 (GLOBE NEWSWIRE) Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that it will move forward with a singular focus on accelerating and expanding its genetically defined disease portfolio, including the mitapivat clinical programs and a robust pipeline of therapeutic candidates, and has entered into a definitive agreement to sell its commercial, clinical and research-stage oncology portfolio to Servier, an independent global pharmaceutical company. Agios will receive a cash consideration of up to $2.0 billion, including $1.8 billion in upfront cash and $200 million in a potential future milestone payment for vorasidenib, as well as 5% royalties on U.S. net sales of TIBSOVO
vimarsana © 2020. All Rights Reserved.